ABVC Biopharma Inc logo

ABVC Biopharma Inc(ABVC)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.91
11/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ABVC

11/18/2026: ABVC (1-star) is currently NOT-A-BUY. Pass it for now.

ABVC Biopharma Inc is a micro-cap clinical-stage biopharmaceutical company focused on developing botanical-derived drugs and medical devices for oncology, central nervous system disorders, and ophthalmology. Its primary business strengths lie in a diverse clinical pipeline targeting high-value indications with potentially lower toxicity profiles. The core investment story centers on potential high-reward value inflection points from successful clinical trial readouts, strategic out-licensing, and medical device commercialization. However, the company faces substantial risks, including persistent financial losses, a lack of commercial revenue, cash burn, and heavy reliance on dilutive capital raises. This stock is best suited for speculative growth investors with a high risk tolerance who are willing to closely monitor clinical trial milestones, regulatory updates, and ongoing liquidity developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe absence of established commercial revenue streams makes it unsuitable for traditional growth mandates.
Momentum investorMixed fitShort-term speculative spikes can occur around clinical trial announcements or financing news.
Value investorWeak fitOngoing operational losses and negative earnings preclude fundamental value investing metrics.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital.
Low-risk investorWeak fitHigh share price volatility and clinical-stage binary risks create substantial risk exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighMicro-cap clinical biotech stocks experience sharp price fluctuations driven by news flow.
Valuation riskMedium / highValuation is speculative and heavily dependent on unproven future pipeline milestones.
Competition risk (clinical biotech and oncology)HighThe company competes with heavily funded entities developing alternative therapies.
Business qualityLowPre-revenue operations and consistent cash burn limit near-term financial resilience.
Dividend incomeLow / noneNo payouts are available for income-focused investors.
Execution riskHighSuccess relies entirely on clinical trial execution and regulatory clearance.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 25.49M USD
Price to earnings Ratio -
1Y Target Price 2.02
Price to earnings Ratio -
1Y Target Price 2.02
Volume (30-day avg) 41.5K shares
Beta 0.5
52 Weeks Range 0.71 - 2.89
Updated Date 11/18/2026
52 Weeks Range 0.71 - 2.89
Updated Date 11/18/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.2

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.0%
Active BUY / eligible
67 / 108
30-Day BUY Count Change
+22
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
43.6%
Active BUY / eligible
17 / 39
30-Day BUY Count Change
+10

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 87.23%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/18/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ABVC receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
ABVC has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+56.2%) is partially offset by negative earnings growth (-61.3%), weak cash generation (FCF margin -375.2%), weak profitability (net margin -993.6%).

Financial Health Rating

★★★★★
ABVC's financial health is soft, with the relatively strongest area being soft profitability, including gross margin of 100.0% and operating margin of -898.5%. Overall financial-health metrics support a 2-star score.

Growth Momentum Score

★★★★★
Revenue growth is ABVC's strongest growth driver at +56.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-61.3%, negative) and free-cash-flow growth (-65.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 4.4% and approximately 81.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 17.90% supports management-shareholder alignment.

Top 5 Institutional Investors

Vanguard Capital Management, LLC 1.40%
Geode Capital Management, LLC 0.85%
Vanguard Fiduciary Trust Co 0.36%
State Street Corp 0.27%
Citadel Advisors Llc 0.27%

Unit Economics (Per $1K Revenue)

★★★★★
ABVC generates approximately $1,000 of gross profit, $-8,985 of operating income, and $-3,752 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 5.32%

Quantitative Style Profile

★★★★★
ABVC has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Biopharmaceutical Research and DevelopmentFuture out-licensing fees, milestone payments, and potential product commercialization sales.The company currently generates little to no revenue and relies on financing and future partnerships.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 28.02M
Price to Sales(TTM) 111.69
Enterprise Value 28.02M
Price to Sales(TTM) 111.69
Enterprise Value to Revenue 184.61
Enterprise Value to EBITDA -1.9
Shares Outstanding 26.98M
Shares Floating 21.96M
Shares Outstanding 26.98M
Shares Floating 21.96M
Percent Insiders 17.9
Percent Institutions 4.36

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.